Calchan Limited is a UK-registered biotechnology company specialising in the early stage development of oral small molecule treatments for pain and inflammation. Calchan has an established management team, led by CEO Brenda Reynolds, who has a successful track record of building UK-based companies and CSO Zahid Ali who has extensive R&D leadership expertise, particularly in the pain and inflammation arena. Calchan’s assets were originally spun out of GlaxoSmithKline (GSK). 

The pipeline of drug candidates targets areas of clear unmet need: the lead drug candidate is a Phase I/II asset CNV2197944, a novel state-dependent calcium channel blocker (Cav2.2). The second program is the preclinical stage apoptosis signal-regulating kinase 1 (ASK1) inhibitor, which is being developed for pain and inflammation. Calchan investors include Apposite Capital, New Leaf Venture Partners and SV Life Sciences as well as GlaxoSmithKline. In addition, Calchan has received a government grant from Innovate UK.